Authors: Didier Lebrec Jaime Bosch Rajiv Jalan Francis J Dudley Rada Jessic Richard Moreau Juan Carlos GarciaPagan Rajeshwar P Mookerjee Eleonora Chiossi Paul L M Van Giersbergen Andjela KusicPajic Jasper Dingemanse
Publish Date: 2011/11/20
Volume: 68, Issue: 5, Pages: 533-541
Abstract
The population consisted of patients with cirrhosis with clinically significant portal hypertension This was a randomized doubleblind multicenter study The patients were randomized 31 to tezosentan 3 mg/h for 2–3 h or placebo HVPG hepatic blood flow HBF ICG method and systemic arterial pressures were measured before and after tezosentan administration Plasma concentrations of tezosentan and ET1 were determined peripherally and in the hepatic veinEighteen patients received tezosentan and six placebo Baseline clinical biochemical and hemodynamic characteristics were balanced between the two groups There was no significant treatment effect on HVPG The extraction ratio 031 the plasma clearance of ICG 280 ml/min and the HBF 1430 ml/min did not show any relevant changes during the infusion of tezosentan and there were no differences between placebo and tezosentantreated patients A linear relationship was observed between the maximumfold increase in ET1 concentration and the steadystate tezosentan plasma concentration r = 082 There was a strong correlation r = 088 between plasma clearance of ICG and that of tezosentan 102 l/h Arterial pressure and heart rate did not significantly change in either group
Keywords: